[June 24, 2016]

Global Hypercholesterolemia Pipeline Report 2016 - Therapeutics Review of 36 Companies & Drug Profile Activity - Research and Markets

Research and Markets has announced the addition of the "Hypercholesterolemia - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Hypercholesterolemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypercholesterolemia and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Hypercholesterolemia Overview
3. Therapeutics Development
4. Pipeline Products for Hypercholesterolemia - Overview
5. Pipeline Products for Hypercholesterolemia - Comparative Analyss
6. Hypercholesterolemia - Therapeutics under Development by Companies
7. Hypercholesterolemia - Therapeutics under Investigation by Universities/Institutes
8. Hypercholesterolemia Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Hypercholesterolemia - Products under Development by Companies
13. Hypercholesterolemia - Products under Investigation by Universities/Institutes
14. Hypercholesterolemia - Companies Involved in Therapeutics Development

• 3SBio Inc.
• Abeome Corporation
• Aegerion Pharmaceuticals, Inc.
• AFFiRiS AG
• Alnylam Pharmaceuticals, Inc.
• Alvogen Korea Co., Ltd.
• AtheroNova Inc.
• BioLingus AG
• Catabasis Pharmaceuticals, Inc.
• Cerenis Therapeutics Holding SA
• Chong Kun Dang Pharmaceutical Corp.
• CymaBay Therapeutics, Inc.
• Daewon Pharm Co. Ltd.
• Eli Lilly and Company
• Esperion Therapeutics, Inc.
• F. Hoffmann-La Roche Ltd.
• Hanmi Pharmaceuticals, Co. Ltd.
• Immune Response BioPharma, Inc.
• Johnson & Johnson
• Kadmon Corporation, LLC
• Kastle Therapeutics, LLC
• Kowa Company, Ltd.
• Kyorin Pharmaceutical Co., Ltd.
• Merck & Co., Inc.
• Omeros Corporation
• Pfizer Inc.
• Planet Biotechnology Inc.
• Progenra, Inc.
• Regeneron Pharmaceuticals, Inc.
• RegenxBio Inc.
• Serometrix, LLC
• Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
• Thetis Pharmaceuticals LLC
• Viking Therapeutics, Inc.
• Zhejiang Hisun Pharmaceutical Co., Ltd.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160624005179/en/

[ Back To TMCnet.com's Homepage ]